Phase 1 BEXMAB data presented at ASH
Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual Meeting - Significant overall Response Rate (ORR) achieved in both HR-MDS (5/5) and HMA-failed MDS (5/5) patients - The vast majority of responses are deep and durable with 7/10 MDS patients achieving CR/mCR and one additional patient transferred to stem cell transplantation Company Announcement, Inside Information TURKU, Finland / BOSTON,